Plain-English translation of NCT06308588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications— and —to treat a specific type of acute lymphoblastic leukemia (a blood cancer) that has a genetic marker called the Philadelphia chromosome. Researchers want to find the safest dose of this medication combination and see how well it works at stopping the cancer or making it undetectable. The study is looking for patients who are newly diagnosed or whose cancer has returned after previous treatment.
Many patients with this type of leukemia cannot tolerate intensive chemotherapy or their cancer returns despite standard treatment. This trial explores whether combining these two targeted medications—which work in different ways—might be more effective and tolerable than existing options.
You likely qualify if…
You likely don't qualify if…
You will receive the treatment in 5 cycles (about 5 months). During each cycle, one medication () is delivered continuously through an IV line, while you take the other medication () by mouth twice daily. After the initial 5 cycles, you continue taking the oral medication alone for as long as it is helping you. Throughout the study, you will have blood tests and medical visits to check how well the treatment is working and to monitor for side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States